Ponlimsi approved as Prolia biosimilar

What this means

Ponlimsi is a biosimilar version of Prolia, a bone-strengthening antibody that works by blocking a protein that breaks down bone tissue. The FDA approved Ponlimsi as a lower-cost alternative for treating osteoporosis, matching Prolia's safety and effectiveness. This could expand access to osteoporosis treatment for more patients while potentially reducing healthcare costs through competition.